What is the recommended approach to evaluate a patient presenting with anosmia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Evaluation of Anosmia

Patients presenting with anosmia require formal psychophysical testing using validated instruments (UPSIT, Sniffin' Sticks, or similar), nasal endoscopy to identify sinonasal pathology, and a focused history targeting onset timing, associated symptoms, and potential COVID-19 exposure.

Initial Assessment Framework

History Taking - Key Elements

The evaluation begins with specific historical details that guide diagnosis:

  • Onset and timing: Sudden versus gradual loss, duration of symptoms, and relationship to other symptoms 1
  • Associated symptoms: Presence of nasal obstruction, rhinorrhea, fever, myalgia, or other systemic symptoms 1
  • COVID-19 context: In the post-pandemic era, anosmia can be an isolated presenting symptom in 26.6% of COVID-19 cases, or occur before other symptoms in 11.8% 1
  • Trauma history: Head injury is a common etiology requiring specific inquiry 2, 3
  • Chronic rhinosinusitis symptoms: This represents the most treatable cause in general practice 2
  • Quality of life impact: Use validated disease-specific questionnaires to document functional impairment 4, 5

Mandatory Physical Examination

Nasal endoscopy is non-negotiable - it identifies sinonasal inflammation, polyps, and structural abnormalities that represent the most frequent and treatable underlying etiologies 4. This single examination can differentiate conductive from sensorineural causes and guide immediate management decisions.

Objective Testing Requirements

Psychophysical Testing

Formal olfactory testing must be performed using validated instruments 1, 4:

  • UPSIT (University of Pennsylvania Smell Identification Test): Country-specific versions available, provides objective quantification
  • Sniffin' Sticks: Alternative validated option
  • Nez-du-Vin: Used in some European centers 1

The case series demonstrates this approach: three healthcare workers with anosmia underwent UPSIT testing, revealing moderate microsmia (25/40), mild microsmia (28/40), and near-normal function (34/40) at day 17, respectively 1. This objective documentation is critical because self-reported symptoms show only slight agreement with objective findings (kappa = 0.13) 6.

Gustatory Testing

When patients report taste loss, perform objective gustatory dysfunction testing with four different flavor solutions, as taste complaints often reflect retronasal olfactory loss rather than true gustatory dysfunction 1, 6.

Diagnostic Algorithm

Step 1: Rule Out Sinonasal Disease

  • Perform nasal endoscopy immediately
  • If inflammation/polyps present: This is your diagnosis - treat accordingly
  • If normal: Proceed to Step 2

Step 2: COVID-19 Consideration

  • If sudden onset anosmia (especially isolated or with mild symptoms): Test for SARS-CoV-2 via RT-PCR 1
  • Anosmia has 67% positive predictive value for COVID-19 and is the strongest symptom predictor 1
  • Combined objective olfactory and gustatory dysfunction with fever and cough increases diagnostic accuracy (adjusted OR = 7.33) 6

Step 3: Identify Other Etiologies

Based on history and examination:

  • Post-viral (non-COVID): History of upper respiratory infection
  • Post-traumatic: Clear head injury history
  • Idiopathic: No identifiable cause after workup 5, 2

Step 4: Advanced Imaging (Selective Use)

  • CT/MRI: Reserved for cases with concerning history, abnormal examination findings, or when diagnosis remains unclear after initial workup 5
  • Not routine: Imaging studies in COVID-19 anosmia showed normal olfactory bulbs, suggesting obstructive rather than neural pathology 1

Critical Pitfalls to Avoid

Do not rely on patient self-reporting alone - the evidence shows poor correlation between subjective complaints and objective testing 6. A patient may report "complete loss" but test with only mild dysfunction, or vice versa.

Do not skip nasal endoscopy - rhinosinusitis is the most readily managed etiology in general practice and requires direct visualization 4, 2.

Do not assume all anosmia is COVID-19 - while important to consider, multiple etiologies exist and require different management approaches 3, 7.

Special Considerations for Healthcare Workers

Healthcare workers with anosmia warrant expedited COVID-19 testing given transmission risk, even with isolated anosmia and no other symptoms 1. The case series demonstrated all three healthcare workers with isolated anosmia tested positive for SARS-CoV-2 1.

Prognosis Documentation

When anosmia is confirmed, document baseline severity objectively. In COVID-19 cases, recovery data shows mean improvement time of 7.2 days, with 13% complete resolution and 14% partial resolution in early studies, though longer-term data suggests 44-73% recovery rates 1. This baseline testing enables monitoring of treatment response or natural recovery.

Quality of Life Assessment

Use validated olfactory-specific quality of life questionnaires to document impact 4, 5. Anosmia profoundly affects safety awareness (fire detection), nutrition, and emotional well-being through loss of memory-associated odors 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.